Alcobra’s ADHD drug meets goals, after excluding some data

(Reuters) – Alcobra Ltd said its drug to treat adult attention deficit disorder met the main goals of a late-stage trial – but only after excluding data from four patients who reacted positively to a placebo. The company's stock lost half its value before the bell to trade at $7.02, after initially rising nearly 28 percent. Alcobra's drug, Metadoxine, was tested in 300 patients as a treatment …

from Content Keyword RSS http://ift.tt/1xVk1KI http://ift.tt/eA8V8J

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s